Virtual Library
Start Your Search
Hirotomo Nakaoka
Author of
-
+
EP1.04 - Immuno-oncology (ID 194)
- Event: WCLC 2019
- Type: E-Poster Viewing in the Exhibit Hall
- Track: Immuno-oncology
- Presentations: 1
- Now Available
- Moderators:
- Coordinates: 9/08/2019, 08:00 - 18:00, Exhibit Hall
-
+
EP1.04-27 - Expression Analysis of Programmed Death-Ligand (PD-L) 1 in Large Cell Neuroendocrine Carcinoma (Now Available) (ID 3112)
08:00 - 18:00 | Author(s): Hirotomo Nakaoka
- Abstract
Background
Programmed death (PD)-1/PD-ligand-1 (PD-L1) signaling is main target of immune-checkpoint therapy for lung cancer. Since PD-L1 expression level is known as an important indicator for patient selection of PD-1/PD-L1 blockade therapy, immunohistochemical analysis using anti-PD-L1 antibody were largely performed in various lung cancer tissues. However, there was few evidences regarding expression pattern of PD-L1 in large cell neuroendocrine carcinoma (LCNEC). In this study, we aimed to clarify the tissue distribution of PD-L1, and gene expression pattern between PD-L1-positive and negative cells in LCNEC.
Method
Lung cancer tissues were derived from patients with LCNEC (n=10) and adenocarcinoma (n=8). All tissues were stained with anti-PD-L1 (SP142, Ventana/Roche), CD8 (T lymphocytes), and PD1 antibody using OptiView DAB IHC systems. To investigate the molecular mechanism of overexpression of PD-L1 in LCNEC, we have also performed microarray analysis of PD-L1-positive and -negative cancer cells in the identical LCNEC patient.
Result
From immunohistochemical staining data, while 25% of adenocarcinoma were PD-L1 positive, 80% of LCNEC were strongly stained by anti-PD-L1 antibody. Invasion of PD-1-positive lymphocytes were also seen around PD-L1 positive lung cancer cells. Microarray data showed that antigen-presenting related genes were dominantly up-regulated in the PD-L1-positive cells.
Conclusion
Our data concluded that the patients with LCNEC might be targets for immune-checkpoint therapy using anti-PD-1 neutralizing antibody.